Literature DB >> 23782016

Genomic instability in multiple myeloma: mechanisms and therapeutic implications.

Paola Neri1, Nizar J Bahlis.   

Abstract

INTRODUCTION: Clonal plasma cells in multiple myeloma (MM) are typified by their nearly universal aneuploidy and the presence of recurrent chromosomal aberrations reflecting their chromosomal instability. Multiple myeloma is also recognized to be heterogeneous with distinct molecular subgroups. Deep genome sequencing studies have recently revealed an even wider heterogeneity and genomic instability with the identification of a complex mutational landscape and a branching pattern of clonal evolution. AREAS COVERED: Despite the lack of full understanding of the exact mechanisms driving the genomic instability in MM, recent observations have correlated these abnormalities with impairments in the DNA damage repair machinery as well as epigenetic changes. These mechanisms and the resulting therapeutic implications will be the subject of this review. EXPERT OPINION: By providing growth advantage of the fittest clone and promoting the acquisition of drug resistance, genomic instability is unarguably beneficial to MM cells, however, it may also well be its Achilles heal by creating exploitable vulnerabilities. As such, targeting presumptive DNA repair defects and other oncogenic addictions represent a promising area of clinical investigation. In particular, by inducing gene or pathway dependencies not present in normal cells, genomic instability can generate targets of contextual synthetic lethality in MM cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23782016     DOI: 10.1517/14712598.2013.814637

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  21 in total

1.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

2.  p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).

Authors:  Phaik Ju Teoh; Omer An; Tae-Hoon Chung; Thamil Vaiyapuri; Anandhkumar Raju; Michal M Hoppe; Sabrina H M Toh; Wilson Wang; Ming Chun Chan; Melissa J Fullwood; Anand D Jeyasekharan; Vinay Tergaonkar; Leilei Chen; Henry Yang; Wee Joo Chng
Journal:  Oncogene       Date:  2022-02-21       Impact factor: 8.756

Review 3.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

4.  FOXM1 is a therapeutic target for high-risk multiple myeloma.

Authors:  C Gu; Y Yang; R Sompallae; H Xu; V S Tompkins; C Holman; D Hose; H Goldschmidt; G Tricot; F Zhan; S Janz
Journal:  Leukemia       Date:  2015-12-09       Impact factor: 11.528

5.  Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.

Authors:  Giada Bianchi; Irene M Ghobrial
Journal:  Curr Cancer Ther Rev       Date:  2014

6.  Biological Insights into Myeloma and Other B Cell Malignancies.

Authors:  Mariateresa Fulciniti; Nicola Amodio; Michele Cea; Patricia Maiso; Abdel Kareem Azab
Journal:  Biomed Res Int       Date:  2016-02-16       Impact factor: 3.411

Review 7.  Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.

Authors:  Antonia Cagnetta; Davide Lovera; Raffaella Grasso; Nicoletta Colombo; Letizia Canepa; Filippo Ballerini; Marino Calvio; Maurizio Miglino; Marco Gobbi; Roberto Lemoli; Michele Cea
Journal:  Biomed Res Int       Date:  2015-10-22       Impact factor: 3.411

8.  Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response.

Authors:  Kenichi Tahara; Makiko Takizawa; Arito Yamane; Yohei Osaki; Takuma Ishizaki; Takeki Mitsui; Akihiko Yokohama; Takayuki Saitoh; Norifumi Tsukamoto; Morio Matsumoto; Hirokazu Murakami; Yoshihisa Nojima; Hiroshi Handa
Journal:  Cancer Sci       Date:  2017-06-25       Impact factor: 6.716

9.  TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.

Authors:  Yi Tao; Guang Yang; Hongxing Yang; Dongliang Song; Liangning Hu; Bingqian Xie; Houcai Wang; Lu Gao; Minjie Gao; Hongwei Xu; Zhijian Xu; Xiaosong Wu; Yiwen Zhang; Weiliang Zhu; Fenghuang Zhan; Jumei Shi
Journal:  Oncotarget       Date:  2017-04-18

10.  A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.

Authors:  Alboukadel Kassambara; Claire Gourzones-Dmitriev; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Hartmut Goldschmidt; Angelos Constantinou; Philippe Pasero; Dirk Hose; Bernard Klein
Journal:  Oncotarget       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.